Cost-Utility Comparison of Down-Titration Strategies for Safer and More Efficient Use of Biologics in Adults with Rheumatoid Arthritis and Psoriatic Arthritis

  • March, Lynette (Chief Investigator)
  • Buchbinder, Rachelle (Chief Investigator)
  • Lassere, Marissa (Chief Investigator)
  • Proudman, Susanna M. (Chief Investigator)
  • Thomas, Ranjeny (Chief Investigator)
  • Schofield, Deborah (Primary Chief Investigator)
  • Xue, Meilang (Chief Investigator)
  • Wechalekar, Mihir D. (Chief Investigator)
  • Whittle, Samuel L. (Chief Investigator)
  • Sinnathurai, Premarani (Chief Investigator)
  • Keen, Helen I. (Associate Investigator)
  • Hill, Catherine (Associate Investigator)
  • Youssef, Peter (Associate Investigator)
  • Benham, Helen (Associate Investigator)
  • Bereza-Malcolm, Lara (Associate Investigator)
  • Willers, Craig (Associate Investigator)
  • Schachna, Lionel (Associate Investigator)
  • Muller, Samuel (Associate Investigator)
  • Perera, Chandima (Associate Investigator)
  • Tymms, Kathleen (Associate Investigator)
  • Worsley, Heidi (Other)

Project: Research

Project Details

Description

Rheumatoid arthritis and psoriatic arthritis can cause severe pain, joint destruction, disability and early death. Biologic drugs can improve these arthritis health outcomes but may also have serious side effects, are very costly and are not cures. Drug-free remission is the next best outcome. This trial aims to identify the optimum dosing strategies for safer and more efficient biologic drug use to help more people with rheumatoid and psoriatic arthritis achieve a drug-free remission.
Short titleMRFF 2021
AcronymUSYD Led
StatusActive
Effective start/end date1/06/2131/05/25